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regression analysis.
Results: Of 134 allo-HSCTs, 29 (21.6%) patients experienced
CMV viremia. Among these patients, median age was 51
years (range 27-67), with 48 episodes of viremia. Nine (31%)
viremic patients developed CMV disease.
CMV disease occurred at a median of 124 days post HSCT
(range 61-322). Patients with CMV disease had a median of 2
viremic episodes before disease (range 1-4). Disease
occurred at a median of 33 days from the start of the last
viremic episode, and 75 days from the start of the ﬁrst
episode of viremia.
On univariate analysis, factors associated with progres-
sion to CMV disease were: steroid-refractory acute GVHD (60
vs. 20%, p¼0.028); number of episodes of viremia >1x103
copies/mL (mean 2.4 vs 1.1, p¼0.016); longer duration of
viremia (mean 38 vs. 22 days, p¼0.01); higher peak viral load
(mean 4.49x105 vs. 8.31x103 copies/mL, p<0.001); and fail-
ure of pre-emptive ganciclovir therapy (50 vs. 10%, p¼0.015).
On multivariate analysis, no factors were signiﬁcantly asso-
ciated with progression to CMV disease.
CMV-related mortality was 33%. All-cause mortality was
signiﬁcantly higher in patients developing CMV disease (100
vs. 35%, log rank test p¼0.0027).
Conclusions: In adult allo-HSCT recipients experiencing 1
episode of CMV viremia, we found by univariate analysis that
patients who developed CMV disease were more likely to
have steroid refractory acute GVHD, more episodes of
viremia >1x103 copies/mL, a longer duration of viremia, and
to have failed ﬁrst-line pre-emptive ganciclovir therapy. This
study, while limited, suggests that these risk factors may be
predictive of CMV disease. Larger, prospective studies are
needed to conﬁrm these risk factors, some of which may be
amenable to more aggressive anti-viral therapy.425
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Introduction: Haplo-HCT is used increasingly as a treatment
for patients with hematologic disorders lacking suitable HLA
matched donors. Graft failure or rejection after myelo-
ablative conditioning (MAC) carries high mortality. We
present case of a patient with graft rejection post haplo-HCT
salvaged with second haplo-HCT using second related
donor.
Case Report: A 28 year old male presented with 3 week his-
tory of progressive weakness. He was severely pancytopenic
withWBC of 2.4, Hb of 4g/dl and platelet count of 14k. Work-
up for secondary causes of pancytopenia was negative.
Complete blood count performed a year earlier was normal.
Bone marrow was 70% cellular with dyserythropoiesis,
decreased megakaryocytes and normal myeloid precursors.
Marrow cytogenetics and Fluorescent in-situ Hybridization
panel for myelodysplastic syndrome was normal. Peripheral
blood ﬂow cytometry for paroxysmal nocturnal hemoglo-
binuria showed a small CD59 deﬁcient red cell clone (1.9%).His cytopenias progressed on high dose steroids. Repeat
marrow 4 weeks later was similar to his original marrow.
Patient had no suitable HLA matched related or unrelated
donor. He underwent Tcell replete peripheral blood stem cell
transplantation (PBSCT) from his haplomatched sister
following MAC with ﬂudarabine (FLU), busulfan and cyclo-
phosphamide (CY) with post transplant CY (PTC) and graft
versus host disease (GVHD) prophylaxis withmycophenolate
mofetil (MMF) and tacrolimus. Cell dose was CD34/kg 5 x 106
and CD3/kg 4.76 x 1010. Pretransplant screening for donor
speciﬁc antibodies (DSA) was negative. Four weeks after
transplant, patient remained severely pancytopenic. Bone
marrow exam showed an acellular marrow and peripheral
chimerism studies were fully recipient. Repeat screening for
DSA was again negative. Patient underwent a second T cell
replete PBSCTon day 39 using his haplomatched father as the
donor. The identical haplotype of the father was different
from his original donor. Patient underwent reduced intensity
conditioningwith FLU, CYand TBI 200 cGywith standard PTC
andGVHDprophylaxiswithMMFand tacrolimus. Post second
transplant, patient neutrophil and platelet engrafted on day
19andday32 respectively. Chimerismpost secondhaplo-HCT
was fully donor. During hospital course patient had multiple
complications. He developed fungemia (Debaryomyces spe-
cies) on day 24 postﬁrst transplant. Post second transplant he
developed oliguric renal failure requiring transient hemodi-
alysis and liver function test (LFT) abnormalities with peak
bilirubin of 12.1mg/dl. Liver biopsy showed drug induced
toxicity. Both his renal function and his LFT have since
improved and are near normal.
Conclusion: Graft rejection in a patient undergoing hap-
loidentical transplant could be successfully salvaged with a
second transplant using a different haploidentical donor and
with reduced intensity conditioning.426
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Background: VTE is a potentially life threatening condition
that requires early recognition and treatment. An increased
incidence of VTE with sirolimus-based immunosuppressive
regimen has been reported in solid organ transplant. Limited
data exist on VTE incidence in allo-HCT with sirolimus-based
GVHD prophylaxis.
Materials and Methods: We analyzed 892 consecutive allo-
HCT recipients between 1/1/2008 and 12/31/2013 at Mofﬁtt
Cancer Center. Baseline characteristics and VTE events were
collected. The association between VTE and baseline char-
acteristics including sirolimus and non-sirolimus GVHD
regimen was assessed using the Cox proportional hazard
model. The signiﬁcance level was set at  0.05. All analyses
were performed using Stata statistical analysis software
version 13.
Table
Patient, disease, and treatment related characteristics (N¼892)
Variables Results
Recipient median age (range), years 53 (19-76)
Recipient gender (%) F ¼ 43%
M ¼ 57%
Donor/recipient gender (%)
F/M 27%
F/F 21%
M/M,F 52%
Donor source (%)
MRD 32%
MUD 43%
MMD 16%
Cord blood 7%
Cell source (%)
PBSC 92%
BM 1%
Cord blood 7%
Diagnoses (%)
AML/MDS 47%
Lymphomas 13%
ALL 14%
Others 26%
Preparative regimen (%)
FLU-BU* 72%
Others 30%
GVHD prophylaxis (%)
Non-sirolimus (MTX/MMF based) 62%
Sirolimus-based 37%
Recipient/Donor CMV serologic status
+/+ 22%
+/- 29%
-/+,- 49%
*includes pharmacokinetically targeted IV busulfan with a median daily
AUC ranging from 3500 to 9000 mmolesmin/L
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most common myeloablative preparative regimens con-
sisted of ﬂudarabine and pharmacokinetically targeted IV
busulfan (FLU-BU with AUC of 3500-9000) in 94% of
cases. The most common reduced intensity regimen used
was ﬂudarabine and melphalan (52%). Baseline charac-
teristics are described in the table. The overall incidence
of VTE was 6.7% for the entire cohort: 7.2% and 6.4% in
the sirolimus and non-sirolimus groups, respectively,
with odds ratio (OR) ¼ 1.14 (95% CI 0. 67-1.95; p¼0.63).
Of the VTE incidence, catheter related VTE were 37% and
36% for the sirolimus and non-sirolimus groups, respec-
tively. Median onset of VTE was 155 and 233 days with
sirolimus and non-sirolimus, respectively. In multivariate
analysis the risk of VTE increased with every 10-year
increment of recipient age with OR ¼ 1.29 (95% CI 1.03-
1.61; p¼0.026).
Conclusion: The use of sirolimus-based regimen did not
increase the incidence of VTE in allo-HCT recipient. Every 10-
year increment in agewas associated with 29% increased risk
of VTE.427
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An allogeneic SCT (alloSCT) with a reduced intensity condi-
tioning regimen (RIC) in ﬁrst remission (CR1) is an attractive
option to fulﬁll the requirements of relatively low cost
without compromising efﬁcacy. The need for consolidation
chemotherapy prior to offering a RIC alloSCT for AML CR1
remains controversial. To evaluate these aspects we under-
took a retrospective analysis of patients with AML CR1 who
received a RIC alloSCT from multiple centers in India.
Data from 8 centers in India was collected between 2005
and 2013. A total of 138 patients fulﬁlled the criteria of AML
CR1 having received an alloSCT with a RIC regimen. The
median age was 34 years (range: 2 e 63) and 60% were
males. The median time from diagnosis of AML to transplant
was 99 days (range: 41 e 504). 123 (89%) were HLA matched
related donors, 3 (2.1%) were MUD transplants and the rest
were HLA mismatched related donors. 70 (51%) received
chemotherapy consolidation prior to transplant, 61 (44%) did
not and data was not available in 7 (5%). 68% of those that
received consolidation received intermediate or low dose
cytosine based regimens. Fludarabine with melphalan
(140mg/m2) (128[93%]) was the most commonly used
regimen. All patients received a PBSC graft with a median
CD34 cell dose of 9.1x106/kg (range: 1.3 e 43). With the
exception of one, all patients engrafted (97% of these ach-
ieved complete chimerism at one month post transplant).
The median time to ANC >500/mm3 was 13 days (range: 7 e
22) and platelet count of >20,000/mm3 was 15 days (range:
0-33). Acute GVHD Grade 2-4 was seen in 29% and of patients
evaluated 62% had chronic GVHD, the majority of these being
limited (61%). The 100 day treatment relatedmortality (TRM)
was 7.5% and the one year TRMwas 25.6%. At amedian follow
up of 24 months the 5 year EFS and OS was 64.05.07 and
71.14.0 respectively. The 5 year cumulative incidence of
relapse was 21.8%. The baseline characteristics as mentioned
above were not signiﬁcantly different between the group
that received consolidation and the group that did not. The
use of consolidation therapy prior to alloSCT did not have a
signiﬁcant impact on EFS or OS.
On a multivariate analysis (after adjusting for those sig-
niﬁcant on univariate analysis and for conventional risk
factors) only CMV reactivation (RR 2.0; 95% CI 1.03-3.87;
P-value 0.042) and fungal infection (RR 7.1; 95% CI 3.154-
16.12; P-value 0.000) had a signiﬁcant adverse impact.
The mean costs of induction chemotherapy for these
patients was US$ 92393596 (n¼74) and for alloSCT it
was 1813813826 (n¼118; costing up to 1 year post
transplant). Induction chemotherapy followed by HLA
matched RIC alloSCT is likely to be the most cost effective
and affordable treatment option for young adults with
AML in CR1 in India. With an average gross net income in
India of US$3500/year the limitation still remains the cost
of treatment and number of centers that can offer this
therapy.
